Translating genomic sequences into antibody efficacy and safety against influenza toward clinical trial outcomes: a case study

Hsih Te Yang, Hong Yang, Jung Hsien Chiang, Shih Jon Wang

研究成果: Review article同行評審

摘要

Antibodies (Abs) are regarded as a newly emerging form of therapeutics that can provide passive protection against influenza. Although the application of genomics in clinics has increased dramatically, the number of therapeutics available for the treatment of many diseases remains insufficient. To translate genomics into medicines, we established a computational workflow to reconstruct 3D structures of hemagglutinin [HA, antigen (Ag)] and Ab for modeling Ab–HA interactions, based on their protein sequences. This platform was capable of testing the validity of bioinformatics predictions against viral neutralization titers for four Abs: CH65, CR8020, C05, and 5J8. By considering off-target effects, CR8020, the only successful candidate in clinical trials, was prospectively identified. Our approach could facilitate the discovery of Ab drugs against infectious diseases.

原文English
頁(從 - 到)1664-1671
頁數8
期刊Drug Discovery Today
21
發行號10
DOIs
出版狀態Published - 2016 十月 1

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

指紋 深入研究「Translating genomic sequences into antibody efficacy and safety against influenza toward clinical trial outcomes: a case study」主題。共同形成了獨特的指紋。

引用此